Loading
PetVivo Holdings, Inc. Stock: price and insider trades · United States
1 insider bought €72k of shares over the last 90 days, the latest by A.L. Sarroff Fund, LLC, filed 21 Oct 2026.
PetVivo Holdings, Inc.: what insiders have been doing
This page follows insider dealings at PetVivo Holdings, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. In the past year (23 October 2025 to 23 October 2026), 107 filings came from 8 insiders.
Every open-market trade in the period is a purchase: 69 purchases worth €782k, from 1 insider, and not a single sale. No amount is published for 2 filings, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. A.L. Sarroff Fund, LLC filed the largest purchase, €277k, on 16 January 2026. Among those who bought: 1 major shareholder.
For context, the typical company on the same exchange (median of 279 companies) published 8 filings over the same period, against 107 filings here. Looking back to 2016, when coverage begins, insiders filed 181 purchases and 5 sales. The 10-K for the year ended 31 March 2026 shows 1.1 m USD of revenue and -10.5 m USD of net income.
The clock since the last published purchase (21 October 2026) now reads 2 days.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
346
Thresholds
n/a
Buy Volume
€1M
181 ops. · all time
Sell Volume
€23,626
5 ops. · all time
Who traded when
BuySaleA.L. Sarroff Fund, LLC36 buys
Since the insiders bought
- +7.9%Entry US$0.70 · Close 20 Oct 2026 US$0.76
- -27.8%Entry US$0.72 · Close at T+365 US$0.52
- -73.3%Entry US$2.08 · Close at T+365 US$0.56
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2026FY ended March 2026 · cache
US$0.69
Analyst consensus
Income statement
RevenueUS$1.1M
Gross profitUS$754.8k66% margin
EBITDA-US$8.9M-777% margin
Net income-US$10.9M-952.8% margin
Valuation
P/Book19.3x
Beta1.34
Balance sheet & cash
Market capUS$26.3M
Total debtUS$376.2k
Free Cash Flow-US$6.1M
Debt / Equity38%
Profitability & ownership
ROE-384.4%
ROA-102.3%
% insiders55.2%
% institutions0.1%
Last declaration on 23 October 2026
Declarations346 total
10,000 shares@ US$0.68Common StockSEC:0001493152-26-048221:0
7,500 shares@ US$0.68Common StockSEC:0001493152-26-048221:1
65,000 shares@ US$0.68Common StockSEC:0001493152-26-048219:0
9,000 shares@ US$0.680.022% mcap3.0% of flowCommon StockSEC:0001099910-26-000286:0
Canonical exit: 11 Jan 2027 (T+90)
4,000 shares@ US$0.700.0099% mcap1.4% of flowCommon StockSEC:0001099910-26-000286:1
Canonical exit: 11 Jan 2027 (T+90)
4,000 shares@ US$0.700.0099% mcap1.4% of flowCommon StockSEC:0001099910-26-000286:3
Canonical exit: 12 Jan 2027 (T+90)
4,286 shares@ US$0.720.011% mcap1.5% of flowCommon StockSEC:0001099910-26-000286:4
Canonical exit: 12 Jan 2027 (T+90)
10,000 shares@ US$0.740.026% mcap3.6% of flowCommon StockSEC:0001099910-26-000286:5
Canonical exit: 13 Jan 2027 (T+90)
3,000 shares@ US$0.700.0074% mcap1.0% of flowCommon StockSEC:0001099910-26-000286:7
Canonical exit: 14 Jan 2027 (T+90)
2,000 shares@ US$0.700.0049% mcap0.7% of flowCommon StockSEC:0001099910-26-000286:8
Canonical exit: 14 Jan 2027 (T+90)
6,969 shares@ US$0.690.017% mcap2.3% of flowCommon StockSEC:0001099910-26-000286:9
Canonical exit: 14 Jan 2027 (T+90)
6,000 shares@ US$0.700.015% mcap2.0% of flowCommon StockSEC:0001099910-26-000286:10
Canonical exit: 14 Jan 2027 (T+90)
3,600 shares@ US$0.700.0089% mcap1.2% of flowCommon StockSEC:0001099910-26-000286:11
Canonical exit: 14 Jan 2027 (T+90)
6,000 shares@ US$0.74870.016% mcap2.2% of flowCommon StockSEC:0001099910-26-000286:13
Canonical exit: 14 Jan 2027 (T+90)
2,000 shares@ US$0.720.0049% mcap0.9% of flowCommon StockSEC:0001493152-26-043551:0
1,497 shares@ US$0.750.0039% mcap0.7% of flowCommon StockSEC:0001493152-26-043551:1
580 shares@ US$0.6870.0013% mcap0.3% of flowCommon StockSEC:0001099910-26-000263:0
Canonical exit: 25 Nov 2026 (T+90)
22,160 shares@ US$0.6790.051% mcap9.6% of flowCommon StockSEC:0001099910-26-000263:1
Canonical exit: 8 Dec 2026 (T+90)
10,974 shares@ US$0.6770.025% mcap4.7% of flowCommon StockSEC:0001099910-26-000263:2
Canonical exit: 9 Dec 2026 (T+90)
24,888 shares@ US$0.6890.058% mcap11.0% of flowCommon StockSEC:0001099910-26-000263:3
Canonical exit: 13 Dec 2026 (T+90)
31,250 shares@ US$0.800.085% mcap1.2% of flowCommon StockSEC:0001493152-26-042324:0
31,250 shares@ US$0.800.085% mcap4.6% of flowCommon StockSEC:0001493152-26-042064:0
31,250 shares@ US$0.780.083% mcap1.2% of flowCommon StockSEC:0001493152-26-042061:0
75,000 shares@ US$0.7711.4% of flowCommon StockSEC:0001493152-26-034280:0
75,000 shares@ US$0.777.8% of flowCommon StockSEC:0001493152-26-034278:0
25 of 346 declarations
About PetVivo Holdings, Inc.
PetVivo Holdings, Inc. is a U.S.-based veterinary biomedical device and animal-health company listed on the NASDAQ in the United States. For French-, Belgian-, and Swiss-based investors, it sits in a niche segment of healthcare with a strong emphasis on intellectual property, product commercialization, and veterinary adoption rather than late-stage pharmaceutical development. The company’s core mission is to manufacture, commercialize, and license innovative medical devices and therapeutics for companion animals, particularly dogs, cats, and horses. Its business model is built around adapting biomaterial and biomedical concepts into practical veterinary products, giving it a differentiated positioning in the animal orthopedics and joint-care market. ([petvivo.com](https://www.petvivo.com/?utm_source=openai))
From a corporate history perspective, PetVivo was incorporated in Nevada in 2009 under a former name and entered its current operating business in 2014 through a reverse merger with PetVivo, Inc., a Minnesota corporation. That history is typical of many micro-cap U.S. listed companies that combine a public listing structure with a proprietary technology platform and a gradual commercialization strategy. The company’s operating footprint is centered in Minneapolis, Minnesota, with SEC filings also referencing Edina, Minnesota, as a principal business location. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1512922/000164117225018617/form10-k.htm?utm_source=openai))
Read moreShow less
PetVivo’s lead commercial product is Spryng® with OsteoCushion® Technology, a veterinarian-administered intra-articular injectable designed to help manage lameness, joint pain, and osteoarthritis. The company also highlights a broader pipeline of products based on its proprietary biomatrix technology, as well as PrecisePRP®, which it describes as an off-the-shelf PRP product intended for veterinary use. In competitive terms, PetVivo is trying to stand out through patent protection, ease of use in clinical practice, and a focus on conditions where veterinarians need alternatives to conventional symptom-management approaches. ([petvivo.com](https://www.petvivo.com/?utm_source=openai))
Geographically, the business remains primarily U.S.-focused, with commercialization efforts supported by a national distributor network and veterinary-industry partnerships. The company has also used trade shows and veterinary conferences to expand awareness and drive adoption. In its public communications, PetVivo has pointed to distribution milestones, including a 2023 announcement that more than 4,500 Spryng syringes had been distributed during the year, which suggests early commercial traction, though investors should treat such figures as an operating milestone rather than a full measure of sustained market penetration. ([petvivo.com](https://www.petvivo.com/news-1/petvivo-holdings-inc-achieves-distribution-milestone-surpassing-4500-syringes-of-spryng-in-2023?utm_source=openai))
Recent developments indicate that management is broadening the product mix and pushing harder on commercialization. In 2025, PetVivo highlighted revenue growth, cost discipline, expansion of its sales force, and a strategic shift toward the companion-animal market, which is larger and faster-growing than the equine-only opportunity. The company also referenced an AI platform intended to reduce veterinary customer acquisition costs, reinforcing the view that management is seeking operating leverage as it scales. Overall, PetVivo remains a high-risk, high-optionality small-cap healthcare name whose equity story depends on clinical adoption, distribution execution, and the ability to convert its patent portfolio into durable commercial value. ([marketscreener.com](https://www.marketscreener.com/news/petvivo-reports-fiscal-q1-2026-results-ce7c51d9df8df226?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
